Centers for Medicare and Medicaid Services March 16 published the final National Coverage Determination that will pay for next generation sequencing in a broad range of cancers.
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
